NovaQuest’s Arbor, Comar Sue Amneal to Block Copies of Nymalize

NovaQuest Capital’s Azurity Pharmaceuticals Inc., its Arbor unit, and their business partner, Morgan Stanley’s Comar LLC, filed a lawsuit alleging that Amneal Pharmaceuticals Inc.’s proposed generic version of Arbor’s Nymalize infringes five patents for the drug, used to prevent brain damage caused by reduced blood flow following a burst blood vessel.

Comar owns two of the patents and licenses them exclusively to Azurity and Arbor, according to a complaint filed Thursday in the U.S. District Court for the District of New Jersey. Each of those patents covers a dispenser for liquid drugs and a method and apparatus ...